TLIS (Talis Biomedical) LT-Debt-to-Total-Asset: 0.22 (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TLIS Talis Biomedical Corp TLIS
28 GF Score
Price $2.84
View Full Analysis

What is Talis Biomedical LT-Debt-to-Total-Asset?

Talis Biomedical TLIS 28 LT-Debt-to-Total-Asset is 0.22 as of Jun. 2024. GuruFocus rates TLIS with a GF Score™ of 28/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Talis Biomedical's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.22.

Talis Biomedical's long-term debt to total assets ratio increased from Jun. 2023 (0.14) to Jun. 2024 (0.22). It may suggest that Talis Biomedical is progressively becoming more dependent on debt to grow their business.

Talis Biomedical  (OTCPK:TLIS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Talis Biomedical LT-Debt-to-Total-Asset Related Terms

Talis Biomedical LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Talis Biomedical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Talis Biomedical LT-Debt-to-Total-Asset Chart

Talis Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 0.00 0.05 0.18 0.18

Talis Biomedical Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.16 0.18 0.20 0.22
TLIS
28GF Score
Talis Biomedical Corp TLIS
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Talis Biomedical LT-Debt-to-Total-Asset Calculation

Talis Biomedical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=16.786/94.674
=0.18

Talis Biomedical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=15.877/72.699
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.22 mean?
Talis Biomedical (TLIS) has a LT-Debt-to-Total-Asset of 0.22 as of Jun. 2024. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Talis Biomedical and its competitors.
Is Talis Biomedical's LT-Debt-to-Total-Asset too high?
Talis Biomedical's current LT-Debt-to-Total-Asset is 0.22. Overall, Talis Biomedical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Talis Biomedical's LT-Debt-to-Total-Asset compare to BJDX and BBLG?
Talis Biomedical's LT-Debt-to-Total-Asset of 0.22 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Talis Biomedical and its competitors. Talis Biomedical's current LT-Debt-to-Total-Asset is 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Talis Biomedical stock overvalued right now?
Talis Biomedical (TLIS) has a current LT-Debt-to-Total-Asset of 0.22. The current LT-Debt-to-Total-Asset is 0.22. Talis Biomedical's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Talis Biomedical (TLIS), the current LT-Debt-to-Total-Asset is 0.22 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Talis Biomedical Business Description

Address 1375 West Fulton Market, Suite 700, Chicago, IL, USA, 60607
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
28GF Score

Get the complete analysis for TLIS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.84
Price